Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?

Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2019-08, Vol.14 (15), p.2083-2100
Main Authors: Aghamiri, Shahin, Mehrjardi, Keyvan Fallah, Shabani, Sasan, Keshavarz-Fathi, Mahsa, Kargar, Saeed, Rezaei, Nima
Format: Article
Language:English
Subjects:
Animals
Cancer therapies
Chemotherapy
Clinical trials
codelivery system
Drug Carriers - chemistry
Drug resistance
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Female
Fever
Genes
Humans
Hyperthermia
hyperthermia therapy
imaging
Immune system
Kinases
lipid-based delivery
Lipids
nanoparticle
Nanoparticles
Nanoparticles - chemistry
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Ovarian Neoplasms - therapy
Pharmaceuticals
Photodynamic therapy
polymeric-based siRNA delivery
Respiratory syncytial virus
RNA Interference
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - genetics
RNA, Small Interfering - therapeutic use
RNAi Therapeutics - methods
siRNA delivery systems
Transplants & implants
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2018-0379